trikafta sale continu cf rais narrow-
moat vertex fair valu estim
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research apr
estim apr
price data apr
rate updat apr
currenc amount express
methodolog valu compani
narrow-moat vertex report strong quarter cystic
fibrosi franchis rais guidanc vertex recent
launch trikafta blew visibl alpha
analyst expect first quarter contribut
million revenu perspect first quarter
last year vertex cystic fibrosi franchis earn
million launch tripl combin
substanti expand compani address patient
popul cystic fibrosi launch
success wide adopt major elig
patient alreadi treatment five
month market revis estim
faster-than-expect uptak increas
fair valu estim per share narrow-moat
total revenu billion last year
rel modest research develop spend
result oper incom million margin
manag increas widen guidanc
present sever uncertainti relat new
patient start given extra precaut physician
interact high-risk patient reimburs
drug unemploy rate climb govern
experi financi strain guid midpoint
billion feel conserv view light strong
first-quart result manag cite pull-
forward revenu patient stock medic
declin complianc time adher highest
patient first start medic explain
look ahead wait approv trikafta
europ model occur late histor
compani face pushback price negoti
reimburs certain european countri recent
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
discov develop small-molecul drug
treatment seriou diseas key drug kalydeco orkambi
symdeko trikafta cystic fibrosi vertex therapi remain
standard care global vertex pipelin also includ therapi
cancer pain inflammatori diseas influenza rare diseas
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
institut clinic econom review icer
privat independ organ led cost-
effect research publish report
suggest trikafta price substanti lower
recommend discount roughli
trikafta list price high price tag alway risk
rare-diseas drug believ payer recogn
transform therapi earn premium price
even icer recogn drug substanti efficaci
award highest rate categori
vertex reimburs agreement europ
symdeko orkambi alreadi includ trikafta pend
approv expect fairli rapid uptak europ even
negoti countri take place
lastli pleas hear one compani
candid antitrypsin defici
pois move ahead phase trial second half
year along alreadi phase vertex
two shot net rare diseas estim
effect aatd treatment could earn peak sale
billion given vertex progress rais
probabl approv opportun howev
anticip challeng patient enrol due
pandem slightli elong develop time
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
equival
net properti plant equip
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
